Shigetaka Suekane

Summary

Affiliation: Kurume University School of Medicine
Country: Japan

Publications

  1. ncbi request reprint HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
    Oncol Rep 18:1463-8. 2007
  2. ncbi request reprint Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
    Cancer Sci 98:1965-8. 2007
  3. ncbi request reprint Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 14:713-8. 2007
  4. ncbi request reprint Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Res 16:341-9. 2007
  5. ncbi request reprint Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, ururume 830 0011, Japan
    Cancer Sci 95:77-84. 2004
  6. ncbi request reprint Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Asahi machi, Kurume, Japan
    Prostate 60:32-45. 2004
  7. ncbi request reprint Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:1555-60. 2006
  8. ncbi request reprint Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
    Masanori Noguchi
    Department of Urology, Kurume University, Kurume, Japan
    Prostate 63:1-12. 2005
  9. doi request reprint Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination
    Nobukazu Komatsu
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer 118:3208-21. 2012
  10. ncbi request reprint Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination
    Masanori Noguchi
    Division of Clinical Research, Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Cancer Biol Ther 10:1266-79. 2010

Detail Information

Publications22

  1. ncbi request reprint HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
    Oncol Rep 18:1463-8. 2007
    ..These results indicate that HLA-G-associated immunoregulation can be overcome and that HLA-G peptide-based anti-cancer immunotherapy is feasible...
  2. ncbi request reprint Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
    Cancer Sci 98:1965-8. 2007
    ..These results encourage further clinical trials of personalized peptide vaccinations...
  3. ncbi request reprint Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 14:713-8. 2007
    ..We investigated whether the quantitative parameters of systematic sextant biopsies were predictive of either adverse pathological findings or disease recurrence after radical prostatectomy (RP)...
  4. ncbi request reprint Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Res 16:341-9. 2007
    ..0347, odds ratio 2.569) were independent predictors of disease death. These encouraging results show the need for further evaluation of the combination of personalized peptide vaccination and low dose of EMP for metastatic HRPC patients...
  5. ncbi request reprint Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, ururume 830 0011, Japan
    Cancer Sci 95:77-84. 2004
    ..We consider that the increase in cellular and humoral immune responses, and decrease in PSA level in some patients justify further development of peptide vaccination for metastatic HRPC patients...
  6. ncbi request reprint Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Asahi machi, Kurume, Japan
    Prostate 60:32-45. 2004
    ..Additive antitumor effects could be achieved by combination of immunotherapy and cytotoxic agents with no or minimum suppression...
  7. ncbi request reprint Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:1555-60. 2006
    ..IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients...
  8. ncbi request reprint Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
    Masanori Noguchi
    Department of Urology, Kurume University, Kurume, Japan
    Prostate 63:1-12. 2005
    ..The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated...
  9. doi request reprint Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination
    Nobukazu Komatsu
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer 118:3208-21. 2012
    ..Because only a subset of patients show clinical responses to peptide-based cancer vaccination, it is critical to identify biomarkers for selecting patients who would most likely benefit from this treatment...
  10. ncbi request reprint Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination
    Masanori Noguchi
    Division of Clinical Research, Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Cancer Biol Ther 10:1266-79. 2010
    ..000282 and P = 0.00045). In contrast, CTL responses were not statistically different between the two groups. Both lymphocyte numbers and IgG response were thus suggested to be biomarkers of cancer vaccine for advanced cancer patients...
  11. pmc A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
    Masanori Noguchi
    Clinical Research Division of the Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    BMC Cancer 13:613. 2013
    ..The purpose of this study was to assess prospectively the PSA kinetics and immune responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC...
  12. ncbi request reprint Early catheter removal 3 days after radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Int J Urol 11:983-8. 2004
    ..We investigated the feasibility and safety of the early removal of urethral catheters 3 days after radical retropubic prostatectomy...
  13. doi request reprint A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Cancer Immunol Immunother 59:1001-9. 2010
    ..PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone...
  14. ncbi request reprint Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
    Tetsuro Sasada
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Fukuoka, Japan
    Eur J Cancer 46:1514-9. 2010
    ..This article discusses possible ways to overcome the hurdles of randomised clinical trials of therapeutic cancer vaccines based on a review of recently conducted clinical trials...
  15. ncbi request reprint Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 57:80-92. 2003
    ..To assess the safety and immune response of a peptide-based immunotherapy for patients with hormone-refractory prostate cancer, a phase I clinical trial was conducted...
  16. doi request reprint A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    BJU Int 102:958-63. 2008
    ..To evaluate, in a prospective, single-blind, randomized trial, the safety and efficacy of a suspension technique for improving early recovery of continence after radical retropubic prostatectomy (RRP)...
  17. doi request reprint Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer
    Yasuhiro Terazaki
    Department of Surgery, Kurume University School of Medicine, Kurume, Japan
    Cancer Sci 103:638-44. 2012
    ..084; respectively). Based on the feasible immune responses in refractory SCLC patients who received at least one cycle (six times) of vaccinations, PPV could be recommended for a next stage of larger-scale, prospective clinical trials...
  18. pmc Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line
    Kosuke Ueda
    Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    PLoS ONE 8:e75463. 2013
    ..In conclusion, the results suggest that the ALDH1-positive cell population rather than SP cells show CSC-LC properties in a RCC cell line, ACHN. ..
  19. doi request reprint Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance
    Tetsuro Sasada
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Immunotherapy 3:1235-51. 2011
    ..A great deal more functional data about TILs needs to be obtained for individual tumors before TILs can be considered as a prognostic parameter in human cancers...
  20. ncbi request reprint Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer
    Kiyoaki Nishihara
    Urology Course, Kurume University School of Medicine, Kurume shi, Fukuoka, Japan
    Int J Urol 21:658-63. 2014
    ....
  21. ncbi request reprint Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma
    Shuichi Sato
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
    Endocr J 57:873-80. 2010
    ..Therefore, thyroid function should be monitored in all patients treated with sunitinib...
  22. ncbi request reprint Identification of target antigens in specific immunotherapy for renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Fukuoka, Japan
    J Urol 177:1157-62. 2007
    ....